Name:	cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived
Namespace Prefix:	cgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.

+ References

No definition available.

+ Details

Name:	cgen_ParticipationRights
Namespace Prefix:	cgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and development expenses milestone payment.

+ References

No definition available.

+ Details

Name:	cgen_ResearchAndDevelopmentExpensesMilestonePayment
Namespace Prefix:	cgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.

+ References

No definition available.

+ Details

Name:	cgen_RoyaltyContingentObligations
Namespace Prefix:	cgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty percentage.

+ References

No definition available.

+ Details

Name:	cgen_RoyaltyPercentage
Namespace Prefix:	cgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Percentage Based On Future Revenues

+ References

No definition available.

+ Details

Name:	cgen_RoyaltyPercentageBasedOnFutureRevenues
Namespace Prefix:	cgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4

+ Details

Name:	us-gaap_GuaranteeObligationsMaximumExposure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:	us-gaap_IncreaseDecreaseInRoyaltiesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cgen_GovernmentAndOtherGrantsAxis=cgen_GileadAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other Commitments [Line Items]
Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security	$ 342
Royalty percentage	1.00%
Research and development expenses milestone payment	$ 225	$ 500	$ 0
IIA [Member]
Other Commitments [Line Items]
Maximum royalty repaid as percentage of grant received	100.00%
Royalty expense	$ 554	1,004	225
Contingent royalty obligations	$ 9,872
IIA [Member] \| Minimum [Member]
Other Commitments [Line Items]
Royalty percentage based on future revenues	3.00%
IIA [Member] \| Maximum [Member]
Other Commitments [Line Items]
Royalty percentage based on future revenues	5.00%
May 2012 Agreement Member
Other Commitments [Line Items]
Agreement, start date	May 09, 2012
Agreement termination description	In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.
May 2012 Agreement Member \| Minimum [Member]
Other Commitments [Line Items]
Participation Rights	4.00%
Antibodies Discovery Collaboration Agreement [Member]
Other Commitments [Line Items]
Contingent fees	$ 0	$ 1,000	$ 750
Gilead Agreement [Member]
Other Commitments [Line Items]
Royalties accrual	$ 704